Last Updated on January 15, 2019 by Sultan Beardsley
Today on September 5th, 2018 BidAskClub upgraded Galectin Therapeutics (GALT) from a ‘hold’ rating to a ‘buy’ rating for it’s investor following. Other analyst have raised their expectations regarding GALT’s performance too. Value engine is even more optimistic. On August 29th they upgraded Galectin Therapeutics from a ‘Buy’ to ‘Strong Buy’. Also, last month HC Wainwright maintained it’s ‘Buy’ rating on GALT and slapped on a $12 price target. A more detailed list of analyst coverage can be found at MarketBeat.
MS Money Moves maintains a $10-$15 price target in the next 12 months for GALT.
GALT’s CEO Dr. Harold Shlevin is presented at the HC Wainwright Global Investor Conference on September 6th. To watch the presentation click here.